OBJECTIVES: The present study investigates early clinical and haemodynamic results with the Freedom SOLO bioprosthesis (FSB) for aortic valve replacement (AVR) in eight Italian institutions.
INTRODUCTION
Stentless bioprostheses have been reported to have more physiological flow and lower transvalvular gradients than traditional stented tissue valves, offering benefits in terms of ventricular function and the regression of left ventricular (LV) hypertrophy [1] [2] [3] . These benefits are more evident in patients with a small aortic annulus, showing in some series a survival advantage [4] [5] [6] . In order to minimize the risk of patient-prosthesis mismatch (PPM) in patients with a small aortic annulus, the use of stentless valves in the supra-annular position seems promising [7, 8] . The Freedom SOLO bioprosthesis (FSB, Sorin Group, Saluggia, Italy) has been designed to have a superior haemodynamic performance due to the supra-annular implantation, which allows the alignment of the valve orifice to the patient's tissue annulus, resulting in the maximization of blood flow. Small series have reported excellent initial results [9, 10] ; however, more studies are needed to confirm these data.
Therefore, the aim of the present study was to assess early clinical and haemodynamic results in patients undergoing aortic valve replacement (AVR) with FSB in a prospective multicenter study of patients referred to eight Italian cardiac surgery centres. All patients underwent resting transthoracic echocardiography (TTE) after AVR; however, since normally and abnormally functioning prostheses may produce similar estimated gradients at rest by TTE [11] , a subgroup of patients underwent a post-operative exercise stress echocardiographic study to provide an integrated assessment of clinical and functional performance of the valve.
METHODS

Study population
From November 2004 to January 2008, a total of 229 patients underwent AVR with an FSB at eight Italian institutions. A group of 104 patients with good acoustic window and LV ejection fraction (LVEF) >40% were included in an echocardiography subgroup study. This inclusion/exclusion criterion is due to the fact that the aim of the present study was to assess the haemodynamic features of the prosthesis without any influence of the ventricular function. A subset of 34 patients underwent semisupine stress echocardiography.
Valve design
The FSB is a stentless valve totally composed of bovine pericardium. The valve is made of two overlapped pericardial sheets in a flat position so that when the leaflets open they recover the original cylindrical configuration; the valve has no fabric reinforcement. The pericardium is fixed in glutaraldehyde at low pressure and the tissue submitted to a detoxification process with homocysteic acid neutralizing the residues of unbound glutaraldehyde groups left over at the end of fixation. The distinctive design allows the FSB to be implanted with a single suture line in a totally supra-annular position.
Surgical technique
All patients were operated on with moderately hypothermic cardiopulmonary bypass. Myocardial protection was achieved with cold crystalloid or blood cardioplegia delivered in the aortic root or coronary ostia or retrogradely, according to the surgeon's preference. The aorta was opened with a transverse incision 1 cm above the sinotubular junction. The aortic valve was excised and the accurate debridement of the annulus from calcium deposits was carried out. Valve sizing was performed using appropriate sizers choosing the labelled valve size corresponding to the sizer that comfortably passed through the annulus. Care was taken not to oversize the valve since the FSB is already upsized by the manufacturer to obtain the best supra-annular seating. Valve implantation was performed as described previously [9] . After weaning from cardiopulmonary bypass, transoesophageal echocardiography was employed routinely to assess valve function, cusp mobility and symmetry and to exclude the presence of any paravalvular leak. The mean duration of aortic cross-clamp time was 77 ± 29 min (range: 34-125 min) and the mean cardiopulmonary bypass time 100 ± 36 min (44-152 min). Implanted prosthetic sizes were as follows: 19 mm (15 patients), 21 mm (73 patients), 23 mm (67 patients), 25 mm (51 patients) and 27 mm (23 patients). Following AVR, oral anticoagulants were not used except in patients with chronic atrial fibrillation and most patients were maintained in long-term treatment with anti-platelet medications.
Transthoracic echocardiography
A complete echocardiographic study was performed using commercially available echocardiographs with the highest possible transducer frequency to obtain the best image resolution and an adequate resolution to obtain a good definition of endocardial borders. Before starting each echo examination, patient's cuff blood pressure, weight and height should be obtained. Echocardiographic studies were performed with the patient at rest in the left lateral position, using a commercially available echocardiograph.
The left ventricle and aorta were recorded from twodimensional (2D) parasternal and four-chamber views. Forward subaortic and aortic Doppler flow velocities were recorded from the apical four-chamber view using the same transducer in the pulse wave and the continuous wave (CW) Doppler mode. Every recording was repeated for at least five cardiac cycles and digitally stored for a subsequent reading.
All investigators were instructed to obtain all the standard echo projections both for cardiac anatomy and transvalvular flow; images were digitally stored at rest and in the case of stress echocardiography at peak exercise. The digital images obtained were sent to the core lab (Institute of Clinical Physiology, Pisa, RS, USA) together with the investigator's case report form. The quality control of echocardiography performance in enrolled centres was previously described in depth [12] . Briefly, the operator from each recruiting centre met the predefined criteria for transthoracic and stress echo reading. At that point, the centre could start recruiting patients and then digitally stored echocardiography from the recruiting centre was directly sent to the core lab.
All echocardiographic data were analysed in the core lab by an experienced echocardiographist blinded to clinical status and valve size. Planimetric measurements included LV diameters and volumes and ejection fraction with the Simpson method. Aortic geometry was determined from the 2D parasternal long-axis view with diameters taken at the level of an outflow tract, the aortic annulus, the sinotubular junction, the sinuses of Valsalva and the ascending aorta. Doppler measurements including peak aortic velocities, aortic valve velocity time integral and LV stroke volume were calculated according to the recommendations of the American Society of Echocardiography [13] and recommendations for the evaluation of prosthetic valves with echocardiography and Doppler ultrasound [14] . The transprosthetic gradients were calculated using a modified instead of a simplified Bernoulli equation. LV mass (LVM) was calculated using the ASE-recommended formula and indexed to the body surface area to give the LVM index (LVMi) [15] .
Exercise stress echocardiography
Patients underwent semi-supine bicycle exercise stress echocardiography according to the European Association of Echocardiography recommendations on stress echocardiography [16] . The stress echo protocol started acquiring apical five-and four-chamber and long-axis views from which baseline (rest) Doppler recordings of transprosthetic, LV outflow tract (LVOT) and tricuspid regurgitant flow were obtained. The patient exercised against an increasing workload in a stepwise fashion from 25 Watts with increments of 25 Watts every 3 min until the target heart rate was achieved or criteria for interrupting the test were encountered. Repeat stress Doppler recordings of the transaortic flow velocity curve by CW Doppler from the apical five-chamber view and the LVOT velocity curve by pulsed Doppler were obtained at rest, before each increase in the workload and at the peak stress.
Follow-up data were obtained by direct visit or (with patients who failed to come back to the hospital) by contacting the referring physicians. Clinical status was carefully assessed at each follow-up eliciting all post-operative complications which occurred after discharge. Adverse events were considered as 'early' when occurring in the first 30 post-operative days and as 'late' when occurring thereafter. Patients discharged from the hospital underwent clinical follow-up and transthoracic echocardiographic evaluation at 1-3 months and at 12 months after AVR.
Statistical analysis
Descriptive statistics were used in order to summarize all demographic, preoperative and surgical characteristics of the patients included in this cohort. The Kaplan-Meier estimates of 1 year overall and event-free survival were calculated and 95% confidence interval (95% CI) using Greenwood's formula. Linearized complication rates were calculated as the number of events divided by the number of patient-years ( pt-yrs) and 90% CIs according to the Poisson distribution. Haemodynamic data were expressed as the mean ± SD, whereas categorical variables were expressed as the counts and percentages. A repeated-measures analysis of variance model was used to investigate the effect of follow-up ( preoperative, 1-3 and 12 months). P-values of <0.05 were considered significant.
RESULTS
Patient characteristics are summarized in Table 1 . Patients discharged from the hospital underwent clinical follow-up between 1-3 months and at 12 months after AVR. The cumulative duration is 240 pt-yrs with a mean follow-up of 382 ± 163 days (range: 0-1181 days); follow-up was concluded in June 2009, with seven (3.0%) patients being lost.
Early mortality and survival
There were seven early deaths (3.1%); of these, six were non-valve-related and were due to the cardiac failure with lowoutput syndrome in four (three of them were coronary patients with LVEF 40-45% and incomplete revascularization) and ventricular arrhythmias in two. One patient died from unknown causes; this death was considered as valve-related. There were 15 late deaths. Of these, two were valve-related (one endocarditis and one unknown) with a linearized incidence of 0.83% pt-yrs (90% CI: 0.26-2.67). Thirteen late deaths were non-valve-related with an incidence of 5.42% pt-yrs (3.44-8.56) and were due to sepsis in four, respiratory failure in three, neoplasia in three, renal failure in one, myocardial infarction in one and post-operative complications after abdominal surgery in one. Actuarial survival was 91.0% (95% CI: 86.4-94.1) at 1 year. Preoperative New York Heart Association (NYHA) Class I 6.6%, Class II 33.6%, Class III 51.1% and Class IV 8.7% (Table 1) ; at last follow-up, 64.0% of patients were in NYHA Class I and 29.6% in Class II and 1.5% in Class III; functional class was not available in 4.9% of patients. 
Post-operative complications
The incidence of major post-operative complications and actuarial freedom are summarized in Table 2 . No cases of valve thrombosis or structural valve deterioration were observed. Thromboembolism was observed in three patients who experienced two early pulmonary embolic episodes and one late transient ischaemic attack after 1 year. Early haemorrhages occurred in two patients (one intraoperative bleeding leading to death in a patient who refused blood transfusion; one gastrointestinal bleeding) and late haemorrhages in two (two gastrointestinal bleeding). In four patients, a late paravalvular leak (two major and two minor) was observed with an incidence of 1.67% pt-yrs (0.73-3.80); one underwent successful reoperation while three were treated conservatively. One patient had early endocarditis resulting in death and one had late endocarditis. The FSB was explanted in two patients because of a large leak in one and due to oversizing in the other.
Transthoracic echocardiography
Pre-operative echocardiographic results, first (1-3 months) and second (12 months) follow-up controls are reported in Table 3 . A significant reduction in mean and peak gradients as well as an increase in the effective orifice area (EOA) was observed in all patients. Pressure gradients and the EOA according to valve size are reported in Table 4 . A statistically significant reduction in the LVMi was found at the first follow-up. A further significant decrease in LVM was observed between 1-3 and 12 months. Finally, the LV ejection fraction showed mild but significant increase at 1-3 and 12 months.
Nevertheless, a limited number of valves (n = 9) showed (Fig. 1 ) surprisingly higher than the expected pressure gradients and the low EOA. Detailed analysis of such cases revealed excessive oversizing (defined as a difference between valve size and aortic annulus >2 mm) in six cases, aortic root calcification in two cases and subaortic hypertrophic obstruction in one case.
The indexed EOA of normally functioning valves showed (Fig. 2) 
Stress echocardiography
Exercise stress echocardiography shows a consistently favourable haemodynamic profile of FSB during stress, but with a certain heterogeneity in valve gradients during stress, regardless of the nominal valve size (Table 5) . During exercise stress echocardiography with a mean peak stress of 75 W and a mean test duration of 8.4 ± 2.9 min, a significant increase in mean and peak gradients, EOA and EOAi was observed. The mean gradient varied from 4.4 ± 1.7 mmHg at rest to 7.0 ± 2.7 mmHg during stress and the peak gradient increased from 12.3 ± 4.5 to 17.6 ± 5.6 mmHg (P < 0.0001). EOA increased from 1.74 ± 0.33 to 1.80 ± 0.36 cm 
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Most currently available stentless valves are more demanding, as inserted using a double suture line, a fairly time-consuming technique, resulting in increased aortic cross-clamp and cardiopulmonary bypass times. That may render the use of such devices less acceptable by many surgeons. Indeed, the FSB has a single suture line allowing a totally supra-annular seating, reducing operative time as showed by our results. Our prospective multicenter study demonstrates that the use of FSB valve is safe showing good patient survival, excellent haemodynamic performance and the low rate of overall as well as valve-related post-operative complications at 1-year followup. Improvement in the functional class was observed as well. A significant reduction in mean gradients as well as an increase in the EOA was observed after AVR at first and at second follow-up control. Particularly, mean and peak gradients ranged from a mean of 4.3-4.8 mmHg and from 11.3 to 12.6 mmHg at 1-3 and 12 months; moreover, as showed in Table 4 , haemodynamic performance improved with increasing valve size. The present study showed that large EOAs and EOAi's remained substantially stable after the first post-operative year. Our data are consistent with previous studies [8, 9] , which demonstrated excellent early clinical and haemodynamic results; in addition, haemodynamic performance may be superior when compared with other stentless valves or cryopreserved homografts [17, 19] . A limited number of valves (n = 9, 8.7%) showed suboptimal haemodynamic performance with surprisingly high-pressure gradients and lower than the expected EOA. The main cause of valve dysfunction (in six cases) was excessive oversizing, causing buckling of tissue with resulting in obstruction very evident in the postoperative TEE examination and in intraoperative findings at reoperation. Since this prosthesis is the only on the market already oversized by the company for optimal supra-annular implantation, any further oversizing may result excessive. As a general consideration and personal experience reoperation is not technically demanding, even at long term, since the amount of pericardial tissue in contact with adjacent native aortic tissue is limited to a 3-mm pericardial strip. This strip in the subcoronary position can be left in place, removing only the valve leaflets. The indexed EOA in our study showed no patients with a severe PPM and only six patients (5.8%) had a mild-moderate PPM (all patients had valve size <25). The lack of a significant transvalvular gradient even in patients with a larger body surface area suggests that PPM is highly unlikely when FSB is used.
Clinically, an improved haemodynamic performance results in LVM reduction. A meta-analysis by Kunadian et al. [20] showed a faster LVM reduction in patients with stentless versus stented aortic valves. In our series, a significant reduction in LVM, LVMi, posterior wall thickness and septal thickness was observed. By extending the follow-up of our patients, we observed a further significant reduction in LV hypertrophy at 12 months, which could be ascribed to expansion and remodelling of the prosthesis. These results are in concordance with a previously published study where the LVM had been found to regress and fall within the normal range at 1 year after implantation of a stentless aortic valve [21] .
During exercise stress echocardiography, the favourable haemodynamic profile of FSB was confirmed. Haemodynamic performance of the FSB under exercise conditions characterized by a modest increase in peak and mean gradients associated with a slight increase in the EOA. These results were also observed in a prospective multicenter trial where the FSB showed a superior haemodynamic performance due to the supra-annular seating, which allows the alignment of the valve orifice to the patient's tissue annulus, resulting in the maximization of the blood flow [22] . Similar haemodynamic performance during stress echocardiography was observed with other stentless valves, such as allografts [23] , freestyle stentless valve [2, 22] and Toronto stentless porcine valve [24] .
This study showed a certain heterogeneity in valve gradients during stress, regardless of the nominal valve size. Mean gradients at peak stress had the strongest correlation with resting EOAi rather than with nominal valve size, making the EOAi most powerful determinant of a peak stress gradient. Stress echocardiography can be the method of choice for evaluating prosthetic valve function and revealing prosthesis dysfunction or PPM during exercise.
Limitations of this study
This is a selected non-randomized comparison which substantially limits the interpretability of the study and it remains unclear what kind of results would have been achieved using alternative methods.
In an attempt to evaluate the 'ideal' haemodynamic performance of FSB in the exercise stress echocardiography subgroup, we selected patients without systolic dysfunction who underwent isolated AVR. This patient selection might have partially biased the results regarding haemodynamic performance, compared with non-selected cohorts of patients. Moreover, since only good acoustic windows, normal LVEF and physical conditions allowing exercise stress are inclusion criteria, the number of candidates in this very old population is limited.
EOA was calculated by continuity equation, which encounters flow velocity in the LVOT and across the valve. Residual calcification or subaortic obstruction can cause errors in EOA evaluation by Doppler echocardiography.
LVM was calculated using the ASE-recommended formula, which involves measurements taken from the short-axis M-mode of the LV. This method makes assumptions regarding LV geometry that may not be valid.
CONCLUSION
Considering the several limitation of the study, we can conclude that the supra-annular implantation technique of the FSB offers an excellent haemodynamic performance both at rest and exercise, supporting other existing data, associated with the rapid regression of LV hypertrophy. The lack of a significant transprosthetic gradient even in patients with a larger body surface area suggests that PPM is highly unlikely when this prosthesis is used.
